• Jenny Y Chien, Stuart Friedrich, Michael A Heathman, Dinesh P de Alwis, and Vikram Sinha.
• Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN 46285, USA. jchien@lilly.com
• Aaps J. 2005 Jan 1;7(3):E544-59.

AbstractPharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation (M&S) are well-recognized powerful tools that enable effective implementation of the learn-and-confirm paradigm in drug development. The impact of PK/PD M&S on decision making and drug development risk management is dependent on the question being asked and on the availability and quality of data accessible at a particular stage of drug development. For instance, M&S methodologies can be used to capture uncertainty and use the expected variability in PK/PD data generated in preclinical species for projection of the plausible range of clinical dose; clinical trial simulation can be used to forecast the probability of achieving a target response in patients based on information obtained in early phases of development. Framing the right question and capturing the key assumptions are critical components of the "learn-and-confirm" paradigm in the drug development process and are essential to delivering high-value PK/PD M&S results. Selected works of PK/PD modeling and simulation from preclinical to phase III are presented as case examples in this article.

13 keywords...

hide…